Nanosystems Biology Cancer Center 2

NSBCC的组织利用了纳米技术科学与工程（加州理工学院）的最新技术，系统生物学的最新技术，以及癌症生物学和临床肿瘤学的最新技术（加州大学洛杉矶分校格芬医学院，琼森综合癌症中心和分子医学转化科学研究所。 NSBCC的愿景是利用癌症生物学和临床肿瘤学系统方法的测量和分析需求，推动新技术的科学和工程，然后通过我们与JCCC和IMED的合作伙伴关系，将这些技术，计算工具和科学转移到扩展的临床研究和临床护理环境中。进一步的发展和影响是通过与营利性合作伙伴的技术商业化。此外，这些技术还可以通过提供生物信息和解决以前不可能解决的问题的办法，开辟新的科学和临床机会。在过去的4年里，我们建立了一个由癌症生物学家，临床肿瘤学家，系统生物学家，物理科学家和工程师组成的社区，他们共同努力，展示了从概念到临床的非常快速的途径，用于体内分子成像诊断，体外诊断和纳米治疗。新的IMED翻译医学设施进一步扩大了我们从基础科学到患者护理的途径。拟议的NSBCC将以目前的势头为基础，重点关注当今癌症生物学和临床肿瘤学中一些最具挑战性问题的核心项目。 主要的目标癌症是胶质母细胞瘤和黑色素瘤，在资金周期的后期阶段应用于卵巢癌。中心主题是癌症的早期检测和靶向治疗技术。对于所有的项目，从台式到床边的路径进行了详细说明。与JCCC和IMED、几家生物技术公司以及其他一些由NCI资助和基金会资助的项目（用于支持相关的临床试验和人体研究）的合作伙伴关系利用了NSBCC的资源。 公共卫生相关性：该CCNE开发的技术和生物信息通过体外诊断和体内分子成像为黑色素瘤、胶质母细胞瘤和卵巢癌的早期检测和信息诊断提供了途径。靶向治疗的直接应用，包括分子靶向治疗、过继性T细胞免疫治疗和siRNA治疗，在拟议的项目中进行了探索。

The NSBCC is organized to take advantage of the state-of-the-art in the science & engineering of nanotechnology (Caltech), the state-of-the-art in the systems biology, and the state-of-the-art in cancer biology and clinical oncology (The UCLA Geffen School of Medicine, the Jonsson Comprehensive Cancer Center & the translational sciences Institute for Molecular Medicine. The NSBCC vision is to utilize the measurement and analysis needs of systems approaches to cancer biology and clinical oncology to drive the science and engineering of new technologies, and to then move those technologies, computational tools and science into an expanded clinical research and clinical care settings through our partnerships with JCCC and IMED. Further development and impact is through commercialization of technologies with for-profit partners. Those technologies can, in addition, open up new scientific and clinical opportunities through enabling access to biological information and solutions to problems that were previously not possible. Over the past 4 years we have built a community of cancer biologists, clinical oncologists, systems biologists, physical scientists and engineers who have worked together to demonstrate extremely rapid pathways from concept to clinic for in vivo molecular imaging diagnostics, in vitro diagnostics, and nanotherapeutics. The new IMED translation medicine facility further expands our avenue from basic science to patient care. The proposed NSBCC will build upon current momentum and will focus on projects that are at the heart of some of the most challenging problems in cancer biology and clinical oncology today. The major targeted cancers are glioblastoma and melanoma, with applications to ovarian cancer during the latter stages of the funding cycle. Central themes are early detection of cancer and enabling technologies for targeted therapies. For all projects, pathways from benchtop to bedside are elaborated. Partnerships with JCCC and IMED, several biotechnology companies, and a number of other NCI-funded and foundation funded programs (for supporting relevant clinical trials and human studies) leverage the NSBCC resources. Public Health Relevance: Technologies and biological information developed by this CCNE provides a pathway for the early detection and informative diagnosis of melanoma, glioblastoma, and ovarian cancers through in vitro diagnostics and in vivo molecular imaging. Direct applications to targeted therapies, including molecularly targeted therapies adoptive T cell immunotherapies, and siRNA therapies, are explored within the proposed Projects.